Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Obesity Surgery
Erschienen in: Obesity Surgery 11/2020

29.08.2020 | Original Contributions

A Preliminary Study on the Influence of Cannabis and Opioid Use on Weight Loss and Mental Health Biomarkers Post-weight Loss Surgery

Erschienen in: Obesity Surgery | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A subpopulation of weight loss surgery (WLS) patients endorse cannabis and/or opioid use; however, impact on post-WLS anxiety and depression is unclear. This study examined the influence of the independent and combined use of cannabis and opioids on (1) depression and anxiety, (2) duodenum serotonin and cortisol, and (3) total percent weight loss.

Materials and Methods

A cross-sectional analysis was conducted among patients (N = 18) who had biomarkers of serotonin and cortisol collected from the duodenum during WLS. Cannabis and opioid use was determined by self-reported lifetime, past-year, and past 30-day use. The Beck Anxiety Inventory and Depression Inventory-II assessed depression and anxiety symptoms. Total percent weight loss was calculated from pre-WLS and post-WLS weight (kg). Chi-squared analyses and t tests were conducted.

Results

Over a quarter (27.8%) were cannabis-only users and 16.7% used a combination of cannabis and opioids. None reported using only opioids in this sample. Combination users presented with greater depressive symptoms (22.7%, p = 0.01) and greater total percent weight loss (34.1%, p = 0.04) than cannabis users (7.8, 23.2%, respectively). Cannabis users had greater serotonin (p = 0.02) and cortisol (p = 0.01) levels than combination users and never users.

Conclusions

Cannabis users had greater cortisol levels than never users and combination users. Combination users had greater weight loss and depression symptoms than cannabis users. Future studies should consider a larger sample size, utilization of a cohort design to address causality, and examination of the type, dose, and route of cannabis and opioid administration to further understand the impact of the combined use of cannabis and opioids post-WLS.
Literatur
1.
2.
Li L, Wu LT. Substance use after bariatric surgery: a review. J Psychiatr Res. 2016;76:16–29.CrossRef
3.
Spadola CE, Wagner EF, Dillon FR, et al. Alcohol and drug use among postoperative bariatric patients: a systematic review of the emerging research and its implications. Alcohol Clin Exp Res. 2015;39(9):1582–601.
4.
King WC, Chen JY, Belle SH, et al. Use of prescribed opioids before and after bariatric surgery: prospective evidence from a U.S. multicenter cohort study. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2017;13(8):1337–46.
5.
King WC, Chen JY, Courcoulas AP, et al. Alcohol and other substance use after bariatric surgery: prospective evidence from a U.S. multicenter cohort study. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2017;13(8):1392–402.
6.
Conason A, Teixeira J, Hsu CH, et al. Substance use following bariatric weight loss surgery. JAMA surgery. 2013;148(2):145–50.
7.
Vidot DC, Prado G, De La Cruz-Munoz N, et al. Postoperative marijuana use and disordered eating among bariatric surgery patients. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2016;12(1):171–8.
8.
9.
10.
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration;2019.
11.
Bauer FL, Donahoo WT, Hollis Jr HW, et al. Marijuana’s influence on pain scores, initial weight loss, and other bariatric surgical outcomes. The Permanente journal. 2018;22:18–002.PubMedPubMedCentral
12.
Rummell CM, Heinberg LJ. Assessing marijuana use in bariatric surgery candidates: should it be a contraindication? Obes Surg. Oct 2014;24(10):1764–70.CrossRef
13.
Donnadieu-Rigole H, Olive L, Nalpas B, et al. Prevalence of psychoactive substance consumption in people with obesity. Substance use & misuse. 2016;51(12):1649–54.
14.
15.
Chaudhry HJ, Hengerer AS, Snyder GB. Medical board expectations for physicians recommending marijuana. Jama. 2016;316(6):577–8.CrossRef
16.
Raebel MA, Newcomer SR, Bayliss EA, et al. Chronic opioid use emerging after bariatric surgery. Pharmacoepidemiol Drug Saf. Dec 2014;23(12):1247–57.
17.
Raebel MA, Newcomer SR, Reifler LM, et al. Chronic use of opioid medications before and after bariatric surgery. Jama. 2013;310(13):1369–76.CrossRef
18.
Cron DC, Englesbe MJ, Bolton CJ, et al. Preoperative opioid use is independently associated with increased costs and worse outcomes after major abdominal surgery. Ann Surg. 2017;265(4):695–701.
19.
Waljee JF, Cron DC, Steiger RM, et al. Effect of preoperative opioid exposure on healthcare utilization and expenditures following elective abdominal surgery. Ann Surg. 2017;265(4):715–21.
20.
Osterhues A, von Lengerke T, Mall JW, et al. Health-related quality of life, anxiety, and depression in bariatric surgery candidates compared to patients from a psychosomatic inpatient hospital. Obes Surg. 2017;27(9):2378–87.
21.
Ivezaj V, Grilo CM. When mood worsens after gastric bypass surgery: characterization of bariatric patients with increases in depressive symptoms following surgery. Obes Surg. 2015;25(3):423–9.CrossRef
22.
Muller A, Mitchell JE, Sondag C, et al. Psychiatric aspects of bariatric surgery. Current psychiatry reports. 2013;15(10):397.
23.
de Zwaan M, Enderle J, Wagner S, et al. Anxiety and depression in bariatric surgery patients: a prospective, follow-up study using structured clinical interviews. J Affect Disord. 2011;133(1–2):61–8.
24.
Ivezaj V, Saules KK, Wiedemann AA. “I didn’t see this coming.”: why are postbariatric patients in substance abuse treatment? Patients’ perceptions of etiology and future recommendations. Obes Surg. 2012;22(8):1308–14.CrossRef
25.
Spadola CE, Wagner EF, Accornero VH, et al. Alcohol use patterns and alcohol use disorders among young adult, ethnically diverse bariatric surgery patients. Subst Abus. 2017;38(1):82–7.
26.
Messiah SE, Vidot D, Spadola C, et al. Self-reported depression and duodenal cortisol biomarkers are related to weight loss. Bariatric Surgical Practice and Patient Care In Press.
27.
Smarr KL, Keefer AL. Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). Arthritis care & research. 2011;63(Suppl 11):S454–66.CrossRef
28.
Beck AT, Brown G, Steer RA. Beck Depression Inventory II. San Antonio, TX 1996.
29.
Osman A, Kopper BA, Barrios FX, et al. The Beck Anxiety Inventory: reexamination of factor structure and psychometric properties. J Clin Psychol. 1997;53(1):7–14.
30.
Beck AT, Steer RA. Beck Anxiety Inventory Manual. San Antonio, TX 1990.
31.
Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–7.
32.
Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264–76.CrossRef
33.
Monteleone P, Brambilla F, Bortolotti F, et al. Serotonergic dysfunction across the eating disorders: relationship to eating behaviour, purging behaviour, nutritional status and general psychopathology. Psychol Med. Sep 2000;30(5):1099–110.CrossRef
34.
Leibowitz SF. The role of serotonin in eating disorders. Drugs. 1990;39(Suppl 3):33–48.CrossRef
35.
Steiger H. Eating disorders and the serotonin connection: state, trait and developmental effects. Journal of psychiatry & neuroscience : JPN. Jan 2004;29(1):20–9.
36.
Kaye WH, Frank GK, Bailer UF, et al. Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies. Physiology & behavior. 2005;85(1):73–81.CrossRef
37.
Kaye WH, Bulik CM, Thornton L, et al. Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am J Psychiatry. Dec 2004;161(12):2215–21.
38.
Akimova E, Lanzenberger R, Kasper S. The serotonin-1A receptor in anxiety disorders. Biological psychiatry. 2009;66(7):627–35.CrossRef
39.
Wade TD, Bulik CM, Neale M, et al. Anorexia nervosa and major depression: shared genetic and environmental risk factors. Am J Psychiatry. Mar 2000;157(3):469–71.
40.
Jimerson DC, Lesem MD, Kaye WH, et al. Eating disorders and depression: is there a serotonin connection? Biological psychiatry. 1990;28(5):443–54.
41.
Hellhammer DH, Wust S, Kudielka BM. Salivary cortisol as a biomarker in stress research. Psychoneuroendocrinology. 2009;34(2):163–71.CrossRef
42.
Choi JC, Chung MI, Lee YD. Modulation of pain sensation by stress-related testosterone and cortisol. Anaesthesia. 2012;67(10):1146–51.CrossRef
43.
Lovallo WR, Enoch MA, Acheson A, et al. Cortisol stress response in men and women modulated differentially by the mu-opioid receptor gene polymorphism OPRM1 A118G. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2015;40(11):2546–54.
44.
Christiansen JJ, Djurhuus CB, Gravholt CH, et al. Effects of cortisol on carbohydrate, lipid, and protein metabolism: studies of acute cortisol withdrawal in adrenocortical failure. J Clin Endocrinol Metab. 2007;92(9):3553–9.
45.
O’Neill PA, Davies I, Fullerton KJ, et al. Stress hormone and blood glucose response following acute stroke in the elderly. Stroke. 1991;22(7):842–7.
46.
Boyar RM, Hellman LD, Roffwarg H, et al. Cortisol secretion and metabolism in anorexia nervosa. The New England journal of medicine.27. 1977;296(4):190–3.
47.
Backman O, Stockeld D, Rasmussen F, et al. Alcohol and substance abuse, depression and suicide attempts after Roux-en-Y gastric bypass surgery. Br J Surg. 2016;103(10):1336–42.
48.
Ranganathan M, Braley G, Pittman B, et al. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology. 2009;203(4):737–44.
49.
Bershad AK, Jaffe JH, Childs E, et al. Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans. Psychoneuroendocrinology. 2015;52:281–8.
50.
Yardeni IZ, Shavit Y, Bessler H, et al. Comparison of postoperative pain management techniques on endocrine response to surgery: a randomised controlled trial. Int J Surg. 2007;5(4):239–43.
51.
Kokka N, Garcia JF. Effects of delta 9-THC on growth hormone and ACTH secretion in rats. Life sciences. 1974;15(2):329–38.CrossRef
52.
Brown TT, Dobs AS. Endocrine effects of marijuana. J Clin Pharmacol. 2002;42(S1):90S–6S.CrossRef
53.
Facchinetti F, Grasso A, Petraglia F, et al. Impaired circadian rhythmicity of beta-lipotrophin, beta-endorphin and ACTH in heroin addicts. Acta Endocrinol. 1984;105(2):149–55.
54.
Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009;25(2):170–5.CrossRef
55.
Seyfried O, Hester J. Opioids and endocrine dysfunction. Br J Pain. 2012;6(1):17–24.CrossRef
Metadaten
Titel
A Preliminary Study on the Influence of Cannabis and Opioid Use on Weight Loss and Mental Health Biomarkers Post-weight Loss Surgery
Publikationsdatum
29.08.2020
Erschienen in
Obesity Surgery / Ausgabe 11/2020
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-020-04828-2

Weitere Artikel der Ausgabe 11/2020

Obesity Surgery 11/2020 Zur Ausgabe

Original Contributions

Are Concomitant Operations During Bariatric Surgery Safe? An Analysis of the MBSAQIP Database

Original Contributions

The Impact of the COVID-19 Pandemic on Bariatric Surgery: Results from a Worldwide Survey

Letter to the Editor

Ketamine and Magnesium: a Successful Combination for Bariatric Surgery

Original Contributions

Weight Loss After RYGB Is Associated with an Increase in Serum Vitamin D in a Population with Low Prevalence of Hypovitaminosis D at Low Latitude

Original Contributions

Improving Access to Bariatric Surgery for Rural and Remote Patients: Experiences from a State-Wide Bariatric Telehealth Service in Australia

Original Contributions

The Impact of Bariatric Surgery on Menstrual Abnormalities—a Cross-Sectional Study

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.